Floatz logo

Ixazomib

Lymphoblastic Lymphoma

Therapeutic Advances in Childhood Leukemia ConsortiumSmall moleculePhase 1/2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
73/ 100

Competitive context

51 Active assets in the Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
City of Hope Medical Center
Phase 4BBB
PEGASPARGASE
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 4BBB
Daunorubicin
City of Hope Medical Center
Phase 4BB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
Thiotepa
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2B

View all 19 →

Same molecule, other indications

Ixazomib is also rated in:

Multiple MyelomaDormant
BB
Indicative ·
66 / 100
View asset →
AmyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
Higher-risk Myelodysplastic SyndromeDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →